ModerateSecond-generation antihistamines×Antiepileptic – selective sodium channel modulator
Updated · Methodology
Mechanism
Cetirizine undergoes little metabolism: two thirds of a dose is excreted unchanged in the urine, and no pharmacokinetic or pharmacodynamic interactions are expected with it (cetirizine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Lacosamide is also eliminated mainly by the kidneys: about 40% of a dose is excreted unchanged in the urine and about 30% as a metabolite with no known activity, formed by CYP3A4, CYP2C9 and CYP2C19 (Vimpat label, US Food and Drug Administration, FDA). Lacosamide has a low interaction potential and less than 15% protein binding, and its SmPC does not mention cetirizine in the interaction section (Vimpat SmPC, European Medicines Agency, EMA). The two drugs overlap in their effect on the nervous system. In sensitive patients, cetirizine with any central nervous system (CNS) depressant can further reduce alertness (cetirizine SmPC, AEMPS), and lacosamide itself causes dizziness, somnolence, balance disorders and attention disturbance (Vimpat SmPC, EMA).
Symptoms
The documents describe no symptoms specific to this combination, but in sensitive patients cetirizine with central nervous system (CNS) depressants can further reduce alertness and impair performance (cetirizine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cetirizine itself most often causes somnolence, fatigue, dizziness and headache (cetirizine SmPC, AEMPS). The most frequent adverse effects of lacosamide are dizziness, headache, nausea and double vision, and somnolence, balance disorders and attention disturbance are common. Lacosamide prolongs the PR interval on the electrocardiogram (ECG), and atrioventricular block, bradycardia and other arrhythmias have been reported after marketing (Vimpat SmPC, European Medicines Agency, EMA).
Management
No document names the pair, and according to the documents the doses of cetirizine and lacosamide need no change (cetirizine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Vimpat SmPC, European Medicines Agency, EMA). In sensitive patients, cetirizine with any central nervous system (CNS) depressant can further reduce alertness (cetirizine SmPC, AEMPS), and lacosamide itself causes dizziness, which can increase the risk of accidental injury and falls (Vimpat SmPC, EMA). Until patients know how lacosamide affects them, they should take care and not drive or operate dangerous machinery (Vimpat SmPC, EMA). Patients who feel drowsy with cetirizine should also avoid driving and dangerous tasks and should not exceed the recommended dose (cetirizine SmPC, AEMPS; Zyrtec label, US Food and Drug Administration, FDA). Use caution with alcohol during cetirizine treatment (cetirizine SmPC, AEMPS), and a pharmacodynamic effect of alcohol with lacosamide cannot be ruled out (Vimpat SmPC, EMA). Lacosamide is used for epilepsy, and cetirizine is used with caution in people with epilepsy or a risk of seizures (Vimpat SmPC, EMA; cetirizine SmPC, AEMPS). Both drugs are eliminated mainly by the kidneys. In renal impairment, the cetirizine dose is reduced according to the table in its SmPC. When creatinine clearance is 30 mL/min or lower, the recommended maximum lacosamide dose is 250 mg per day (cetirizine SmPC, AEMPS; Vimpat SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Cetirizina, Zyrtec 10 mg (nº registro 58481), secciones 4.5 y 4.7 (2023)– AEMPS, CIMA, nº registro 58481, revisión 09/2023, secciones 4.5 y 4.7
- FDA: Zyrtec Allergy (cetirizine) drug facts label (2025)– FDA, DailyMed setid b165db38-b302-4220-8627-77cb07bb078c, Kenvue, revised 10/2025, Warnings
- EMA: Ficha técnica: Lacosamida (EU/1/08/470), sección 4.5 (2026)– EMA, Vimpat 100 mg comprimidos recubiertos con película (UCB Pharma, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08470005, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.1, 4.3, 4.4, 4.5, 4.7, 4.8 y 5.2
- FDA: Vimpat (lacosamide) prescribing information (2026)– FDA, DailyMed, UCB, Inc., setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2, v63, 05/2026, sections 4, 5.2, 5.3, 7.2, 8.2 and 12.3